AnteNOR

July – December 2021

• AnteNOR project kick-off
• Green ICT project was mentioned in Delfi Ärileht article
• Mapped and interviewed Norwegian key stakeholders in the field of breast cancer and breast cancer mammography screening
• Applied and received the ethical commitee approval for genetic analysis study
• Analysis of Norwegian genetic data started
• Antegenes became a member of Oslo Cancer Cluster
• Presentation about Antegenes and AnteNOR project at Oslo Cancer Cluster virtual annual meeting on 15th of December

January – June 2022

• Started cooperation with Oecona AS
• Participated in EXPO 2020 Dubai for international scientific cooperations
• Green ICT project was mentioned in e-Estonia blog article.
• Development of the cost-benefit simulation study for Norwegian medical setting
• AnteNOR seminar was organized in Oslo by Oslo Cancer Cluster and Antegenes
• AnteNOR project clinical pilot study protocol created and ready
• Application for conducting the AnteNOR clinical pilot is submitted to Regional Ethical Commitee

July – December 2022

• Approval of the Ethics Committee to implement study in Oslo University Hospital and Vestre Viken Hospital was obtained.
• Clinical study was registered in the ClinialTrials.gov database.
• Clinical study logistics pathways were developed,  study assistant was involved by Vestre Viken Hospital.
• Retrospective performance assessment of Antegenes PRS in Norwegian data has been conducted. Initial results have been compiled and presented as a poster at the Nordic Society of Human Genetics and Precision Medicine 2022 conference “Precision Medicine Research And Implementation: Rebooting In The Nordics Post-Covid” (3-4 November 2022, Copenhagen, Denmark) (Akdeniz et al. “Implementation of polygenic risk score guided breast cancer prediction in Norwegian data”).
• Oecona developed the cost-utility preliminary model for Norwegian medical setting. Collaboration with health economists of Sweden was launched.
• Norway specific health technology assessment and implementation options specific to Norwegian healthcare were developed.
• The article “Preventing breast cancer in Norway” was written and published on Oslo Cancer Cluster website.

January – June 2023

• A cost-benefit study assessing a AnteBC based breast cancer screening routine in comparison with alternatives is completed.
• Information from external and internal sources for health technology assessment was collected and developed.
• The clinical pilot was launched in February at Oslo University Hospital and Vestre Viken Hospital.
• AnteBC polygenic risk model is recalibrated for use in the Norwegian population. The manuscript is under submission.
• Genetics guided breast cancer screening program policy document draft has been developed and introduced to partners and external experts in Norway and the UK.
• Three articles were written and published on the Oslo Cancer Cluster website:

1. On 23 February: the clinical study launch.
2. On 30 May: Antegenes support to the recent guidance from the American College of Medical Genetics and Genomics.
3. On 27 June: the AnteNOR project results were presented at the meeting organized by the Norwegian Cancer Mission Hub.

July – December 2023

The health technology assessment report to support the development of a reimbursement application in Norway has been finalized and the dossier developed.

• The clinical pilot at Oslo University Hospital and Vestre Viken Hospital was carried out.
• Data from the clinical pilot was analyzed and preliminary results were presented at the AnteNOR results presentation seminar on 6 of November in Oslo.
• A comparison of polygenic risk scores’ performance to current breast cancer risk assessment methods is completed.
• The development of genetics guided breast cancer screening program policy document was continued.
• The manuscript titled „A Breast Cancer Polygenic Risk Score is feasible for risk-stratification in the Norwegian population“ was published in the journal MDPI Cancer. Read more in the journal MDPI Cancer.
• On 12 October the article “Implementation of Risk-Stratified Breast Cancer Prevention With a PRS test in Clinical Practice” was published in SAGE Journals. Read more in the SAGE journal.
• Peeter Padrik participated in the European Hereditary Tumour Group Annual Meeting in Vilnius, where he gave a presentation on the topic “Clinical Applications of Breast Cancer Polygenic Risk Score Testing in Women”.
• Two articles were written and published on the Oslo Cancer Cluster website:

1. On 6 September: the Norwegian clinical and genetic data analyses.
2. On 10 November: the AnteNOR results presentation seminar.